Jafron Financial Statements From 2010 to 2024

Stocks . China . 
Stock . Jafron Biomedical Co
300529 Stock   30.48  0.41  1.36%   
Jafron Biomedical financial statements provide useful quarterly and yearly information to potential Jafron Biomedical Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Jafron Biomedical financial statements helps investors assess Jafron Biomedical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Jafron Biomedical's valuation are summarized below:
Gross Profit
2.3 B
Profit Margin
0.3056
Market Capitalization
24.3 B
Enterprise Value Revenue
8.8316
Revenue
2.6 B
We have found seventy-three available fundamental trends for Jafron Biomedical, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Jafron Biomedical regular market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Jafron Biomedical Total Revenue

1.22 Billion

Check Jafron Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jafron Biomedical's main balance sheet or income statement drivers, such as Interest Expense of 57 M, Selling General Administrative of 363.6 M or Total Revenue of 1.2 B, as well as many indicators such as . Jafron financial statements analysis is a perfect complement when working with Jafron Biomedical Valuation or Volatility modules.
  
This module can also supplement various Jafron Biomedical Technical models . Check out the analysis of Jafron Biomedical Correlation against competitors.

Jafron Biomedical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.8 B5.5 B2.3 B
Slightly volatile
Other Current Liabilities4.6 M4.9 M66.9 M
Pretty Stable
Total Current Liabilities870.9 M829.4 M288 M
Slightly volatile
Total Stockholder Equity1.8 B3.1 B1.5 B
Slightly volatile
Other Liabilities151.9 M144.7 M60 M
Slightly volatile
Retained Earnings1 B2 B863.9 M
Slightly volatile
Accounts Payable142.4 M135.6 M45.7 M
Slightly volatile
Cash3 B2.8 B1.2 B
Slightly volatile
Other Assets272.2 M259.2 M93.8 M
Slightly volatile
Net Receivables118.9 M74.9 M102.2 M
Slightly volatile
Inventory404.2 M385 M124.5 M
Slightly volatile
Other Current Assets26.1 M17.3 M22.9 M
Slightly volatile
Total Liabilities2.5 B2.4 B668.1 M
Slightly volatile
Intangible Assets53.5 M100.4 M46.8 M
Slightly volatile
Common Stock972.6 M926.3 M471.6 M
Slightly volatile
Property Plant Equipment1.5 B1.5 B589.2 M
Slightly volatile
Good Will11.6 M12.2 M20.3 M
Slightly volatile
Net Tangible Assets2 B3.7 B1.6 B
Slightly volatile
Deferred Long Term Liabilities43.4 M41.3 M14.5 M
Slightly volatile
Total Current Assets2.1 B3.3 B1.4 B
Slightly volatile
Non Current Assets Total1.3 B2.2 B862.9 M
Slightly volatile
Non Currrent Assets Other102.3 M107 M56.9 M
Slightly volatile
Short Term Investments137.5 M172.5 M127.3 M
Slightly volatile
Non Current Liabilities Total1.6 B1.6 B385.1 M
Slightly volatile
Common Stock Shares Outstanding880 M807.6 M801.4 M
Slightly volatile
Net Invested Capital3.4 B4.8 B2.3 B
Slightly volatile
Net Working Capital2 B2.5 B1.4 B
Slightly volatile
Long Term Investments72.5 M81.5 M88.8 M
Slightly volatile
Capital Stock743.6 M807.6 M542.5 M
Slightly volatile
Property Plant And Equipment Net1.4 B1.8 B892.9 M
Slightly volatile
Other Stockholder Equity148.7 M141.6 M39.1 M
Slightly volatile
Property Plant And Equipment Gross1.6 B2.1 B1 B
Slightly volatile
Capital Lease Obligations11.5 M11.3 M12.4 M
Slightly volatile
Long Term Debt1.2 B1.4 B951 M
Slightly volatile

Jafron Biomedical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative363.6 M664.4 M315.7 M
Slightly volatile
Total Revenue1.2 B1.9 B1.1 B
Slightly volatile
Operating Income528.6 M523.2 M457.2 M
Slightly volatile
Research Development257.6 M245.4 M84.3 M
Slightly volatile
Cost Of Revenue196.3 M384 M169.9 M
Slightly volatile
Income Before Tax549.8 M521 M475.9 M
Slightly volatile
Income Tax Expense255.2 M243.1 M99.7 M
Slightly volatile
Gross Profit1.4 B1.5 B974.8 M
Slightly volatile
Other Operating Expenses47.8 M45.5 M20.9 M
Slightly volatile
Net Income From Continuing Ops615 M425.7 M443.3 M
Slightly volatile
EBIT1.6 B1.5 B644 M
Slightly volatile
Total Operating Expenses918.5 M1.4 B656.2 M
Slightly volatile
Net Income Applicable To Common Shares1.4 B1.4 B583.5 M
Slightly volatile
Net Income618.2 M436.5 M445.2 M
Slightly volatile
Minority Interest12.2 M10.8 M7.6 M
Slightly volatile
Tax Provision119.8 M95.3 M81.8 M
Slightly volatile
Net Interest Income34.3 M32.7 M12.5 M
Slightly volatile
Interest Income92.4 M88 M23.6 M
Slightly volatile
EBITDA944.9 M1.3 B637.9 M
Slightly volatile
Reconciled Depreciation51.4 M94.8 M32.8 M
Slightly volatile

Jafron Biomedical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities10.8 M10.3 M4.2 M
Slightly volatile
Dividends Paid589.9 M561.8 M240.2 M
Slightly volatile
Capital Expenditures209.4 M247.3 M179.9 M
Slightly volatile
Total Cash From Operating Activities518.8 M916.7 M448.5 M
Slightly volatile
Other Cashflows From Investing Activities19.1 M33 M16.1 M
Slightly volatile
Change In Cash306.6 M215.2 M205.8 M
Slightly volatile
Depreciation99.5 M94.8 M33 M
Slightly volatile
Change To Operating Activities11.6 M9.5 M8.6 M
Slightly volatile
Net Income618.2 M436.5 M445.2 M
Slightly volatile
End Period Cash Flow1.8 B2.7 B1.3 B
Slightly volatile
Free Cash Flow485.5 M669.5 M297.3 M
Slightly volatile
Begin Period Cash Flow1.7 B2.5 B1.2 B
Slightly volatile
Other Non Cash Items76.1 M72.5 M14.1 M
Slightly volatile
Net Borrowings793.8 M893.1 M972.4 M
Slightly volatile

About Jafron Biomedical Financial Statements

Jafron Biomedical stakeholders use historical fundamental indicators, such as Jafron Biomedical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Jafron Biomedical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Jafron Biomedical's assets and liabilities are reflected in the revenues and expenses on Jafron Biomedical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Jafron Biomedical Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue1.9 B1.2 B
Cost Of Revenue384 M196.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Other Information on Investing in Jafron Stock

Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Cash Flow
Statement
Details
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY